Ireland to India: Syringe Import Trade Route

The Ireland to India Syringe corridor is one of India's established pharmaceutical import routes from Ireland, with 22 shipments documented worth a combined $366.5K USD. The route is dominated by SANOFI R&D , which alone accounts for roughly 48% of all import value, reflecting the consolidated nature of Ireland's syringe export sector.

Across 14 active Ireland suppliers, the average shipment value stands at $16.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 75% of all shipments, consistent with syringe's non-urgent bulk-order profile.

Shipment activity peaks during January–March, with an average transit time of 17 days port-to-port. The route has recorded an annual growth rate of 12.8%, placing it at rank #20 among India's top syringe import origins globally.

On the Indian buyer side, key Indian importers include SANOFI HEALTHCARE INDIA PRIVATE LIMITED , LOTUS LABS PRIVATE LIMITED, CURATEQ BIOLOGICS PRIVATE LIMITED and 10 others. SANOFI HEALTHCARE INDIA PRIVATE LIMITED is the single largest Indian importer with 3 shipments valued at $176.1K USD.

India's syringe imports from Ireland are driven primarily by a handful of large-scale Ireland manufacturers. SANOFI R&D with 3 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 14 active exporters signals a competitive but concentrated market — Indian buyers benefit from Ireland supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — SANOFI R&D , M S ALMAC CLINICAL SERVICES, ABACUS MEDICINE PHARMA SERVICES LTD — together account for 76% of total trade value on this route. The average shipment value of $16.7K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as (ncv) (import for clinical trail use) sar440340 (regn3500) / itepekimab 300mg/ml 2ml in pre-filled syringe or placebo and for clinical trial- active xolair omalizumab 150mg/ml prefilled syringe foc, suggesting that Indian buyers tend to consolidate orders across related product lines from the same Ireland supplier.

On the buying side, SANOFI HEALTHCARE INDIA PRIVATE LIMITED is the largest importer with 3 shipments worth $176.1K USD — representing 48% of all syringe imports from Ireland on this route. A total of 13 buyers are active on this corridor.